‘Food noise’—a term gaining traction in obesity research—refers to persistent and disruptive cognitive preoccupation with food, manifesting as uncontrollable, negative, and distracting thoughts that impede healthy eating behaviors. Although anecdotal evidence suggested that GLP-1 receptor agonists, a class of drugs initially developed for glycemic control in diabetes management, show promise in reducing these maladaptive food-related cognitions, this study provided critical empirical validation by quantitatively measuring changes in food noise under real-world conditions.

In this observational cohort, 417 adult participants engaged in a digital behavioral weight management platform modeled after Weight Watchers programs. The cohort was stratified into two groups: those initiating GLP-1 receptor agonists adjunctively with behavioral therapy (Weight Watchers Med+) and those receiving behavioral therapy alone without GLP-1 RA use (Weight Watchers Core+). Notably, individuals already on any weight loss pharmacotherapy at baseline were excluded to ensure the purity of treatment effects.

The core investigation utilized the Food Noise Questionnaire (FNQ), a rigorously validated psychometric tool assessing cognitive intrusions related to food via five targeted, Likert-scale items. Each item rates the frequency and intensity of food-related thoughts that are constant, uncontrollable, excessive, negatively impactful, and distracting. Scores range from zero to 20, encapsulating the severity of an individual’s food noise experience. Participants completed the FNQ at baseline and one month later, aligning with digitally recorded body weight measurements.

Initial FNQ assessments revealed higher baseline food noise in the GLP-1 RA group, averaging scores of 13.1 compared to 10.7 in the control group. After one month, the Med+ group exhibited a pronounced mean FNQ reduction to 8.7—a decrease reflecting a significant alleviation in intrusive food thoughts. Conversely, the Core+ group showed a more modest reduction, dropping to 9.7. Crucially, statistical models accounting for baseline differences confirmed a robust effect of GLP-1 receptor agonist therapy on diminishing food noise, highlighting a mean adjusted decrease three points greater than behavioral therapy alone.

Importantly, this attenuation of food noise occurred concomitantly with behavioral interventions, underscoring a synergistic interplay between pharmacologic appetite regulation and cognitive-behavioral strategies. This neuropsychological shift may represent an early mechanistic indicator for the efficacy of weight management regimes incorporating GLP-1 receptor agonists, beyond mere caloric restriction and counseling sessions.

Ongoing analyses aim to dissect the correlation between weight changes and improvements in food noise metrics, potentially elucidating causal pathways linking neurochemical modulation to behavioral outcomes. Understanding whether reduced food noise leads to sustained weight loss or improved metabolic parameters will be pivotal for clinical translation and personalized treatment algorithms.

The implications of these findings extend deeply into obesity medicine and behavioral neuroscience. Persistent food thoughts have long been recognized as obstacles to dietary self-regulation, often culminating in relapse and weight regain. GLP-1 receptor agonists appear to directly modulate central nervous system circuits governing appetite, reward processing, and cognitive control, thereby dampening cognitive interference—phenomenologically captured as food noise—which in turn may facilitate improved adherence to nutritional recommendations.

Further research is warranted to explore the temporal dynamics of food noise reduction over extended treatment periods. Longitudinal investigations could reveal whether these cognitive benefits are sustained or if compensatory neuroadaptations diminish efficacy. Additionally, dissecting the neurobiological substrates influenced by GLP-1 receptor agonists could identify novel targets for obesity therapies that more effectively integrate pharmacologic and psychological aspects.

The research team, anchored at the Pennington Biomedical Research Center—a hub for metabolic and obesity science—has set a precedent integrating quantified patient-reported cognitive measures within large-scale behavioral health interventions. Their innovative use of the FNQ demonstrates the importance of subjective psychological constructs in the context of objective therapeutic outcomes, bridging a gap traditionally overlooked in weight management trials.

It is noteworthy that the study sample predominantly comprised older, white females with an average BMI in the mid-thirties, a demographic characteristic that may influence generalizability. Future randomized controlled trials with diversified cohorts will be essential to confirm these preliminary but promising results across different populations, including varying ages, ethnicities, and comorbid conditions.

The confluence of behavioral science, pharmacotherapy, and digital health platforms exemplified in this work marks a paradigm shift in tackling obesity, a multifactorial disease requiring multifaceted interventions. By illuminating a measurable psychological marker—food noise—and demonstrating its modulation, this research paves the way for more nuanced, integrative therapeutic frameworks.

As obesity prevalence escalates globally, the development and validation of tools like the Food Noise Questionnaire offer clinicians and researchers tangible means to quantify subjective cognitive states, personalize interventions, and potentially predict patient responsiveness to weight loss therapies incorporating GLP-1 receptor agonists. Ultimately, such advancements promise to enhance treatment adherence, efficacy, and patients’ quality of life.

For further details on this innovative metric, the Food Noise Questionnaire and its translations are accessible through the Pennington Biomedical Research Center’s dedicated portal. The ongoing commitment of this institution to tackling obesity through collaborative, multidisciplinary research continues to propel the field toward breakthroughs with meaningful real-world impact.

Subject of Research: People

Article Title: Changes in Food Noise in Two Weight Management Programs: Effects of GLP-1 Receptor Agonists

News Publication Date: (Not specified in the source)

Web References:

• Food Noise Questionnaire: www.pbrc.edu/fnq
• Link to publication on FNQ: https://onlinelibrary.wiley.com/doi/10.1002/oby.24216

Image Credits: PBRC

Keywords

Body weight, Weight loss, Weight gain, Food science, Foods, Obesity, Childhood obesity, Drug research, Clinical research, Scientific facilities, Medical research facilities, Research universities

Metformin, originally developed in the 1950s, has gained recognition not only for its efficacy in managing blood glucose levels in adults with diabetes but also for its potential benefits in mitigating obesity-related complications. Its mechanism of action is multifaceted, encompassing enhanced insulin sensitivity, reduced hepatic glucose output, and an overall effect on energy metabolism. However, the implications of metformin use in pediatric populations, particularly in terms of weight management and metabolic health, remain a subject of intense investigation.

The study led by Acikan and colleagues investigate the specific effects of short-term metformin use on zinc levels and adipose tissue-derived biomarkers in children grappling with obesity and insulin resistance. Understanding the relationship between these variables is crucial, as zinc is an essential trace element that plays a vital role in various physiological processes, including insulin signaling and glucose metabolism. The interdependence between zinc status and adipose tissue function underscores the importance of further exploration in this area.

Obesity during childhood has been linked to a myriad of long-term health complications, including cardiovascular disease and type 2 diabetes. The underlying mechanisms often involve dysregulation of insulin signaling pathways, which can perpetuate a cycle of increased fat storage and impaired glucose utilization. Thus, addressing insulin resistance effectively is not only a matter of immediate health but also pivotal in preventing chronic diseases later in life. Acikan et al. provide essential insights into the potential of metformin to disrupt this negative feedback loop.

One of the significant findings of the study is the impact of metformin on zinc levels, which could potentially translate into improved metabolic outcomes. Zinc’s role in insulin secretion and action makes it a critical player in maintaining glucose homeostasis. Moreover, the modulation of zinc levels may influence adipose tissue function, thereby affecting the production of cytokines and adipokines that regulate inflammation and energy balance. The mechanisms through which metformin exerts its effects on zinc levels and adipose tissue biomarkers are crucial for understanding its suitability as a treatment option for pediatric obesity.

The authors meticulously describe the methodology employed in their study, involving a carefully selected cohort of children diagnosed with obesity and insulin resistance. By employing rigorous clinical protocols, the researchers were able to monitor changes in zinc levels, as well as the secretion of adipose tissue-derived biomarkers, during the short-term administration of metformin. This attention to detail not only enhances the credibility of the findings but also lays the groundwork for further exploration into the pharmacological management of obesity in children.

In addition, the study emphasizes the importance of conducting long-term research to ascertain the continued effects of metformin on these biomarkers and overall metabolic health. While short-term benefits are promising, the potential for sustained improvements and any long-lasting impacts on growth and development in children necessitate further investigation. The careful consideration of the long-term implications of pharmacological treatments in young populations is crucial to ensure safety and efficacy.

Moreover, the research highlights the interconnection between dietary factors and pharmacological interventions. While medications like metformin can offer significant benefits, they are most effective when combined with lifestyle modifications such as healthier dietary patterns and increased physical activity. Thus, an integrated approach comprising medication, nutrition, and exercise should be considered essential for the comprehensive management of obesity and related disorders in children.

As the obesity epidemic continues to evolve, new strategies must be developed to address the multifaceted issues surrounding childhood obesity. The insights provided by Acikan and colleagues contribute to the growing body of evidence suggesting that pharmacotherapy may play a role in managing obesity and insulin resistance. Their findings encourage healthcare practitioners to explore the potential of metformin as part of a broader treatment plan that incorporates lifestyle interventions.

In conclusion, the exploration of metformin’s role in managing obesity-related biomarkers in children is a promising avenue of research. As we advance our understanding of the pharmacological and nutritional interventions available, it is essential to prioritize the health and well-being of our children. Future studies will undoubtedly contribute to the evolution of clinical approaches aimed at combating childhood obesity and its associated complications.

Ultimately, the promising outcomes of Acikan et al.’s work not only spotlight the potential of existing medications like metformin but also underscore the importance of ongoing research in the realm of pediatric obesity. A paradigm shift towards recognizing the complexities of childhood obesity will be critical in enabling effective interventions that can positively impact future generations.

The findings thus not only enrich the current understanding of metabolic health in children but also ignite a conversation about the holistic management of pediatric obesity, incorporating not just medication but a multi-faceted strategy that holistically addresses underlying issues.

By bridging the gap between pharmacological and lifestyle approaches, we can pave the way for improved health outcomes and a brighter future for children facing the challenges of obesity and insulin resistance.

Subject of Research: The effects of short-term metformin treatment on zinc and adipose tissue-derived biomarkers in children with obesity and insulin resistance.

Article Title: The role of short-term metformin in regulating zinc and adipose tissue-derived biomarkers in children with obesity and insulin resistance.

Article References:

Acikan, H., Isik, A., Sarikaya, E. et al. The role of short-term metformin in regulating zinc and adipose tissue-derived biomarkers in children with obesity and insulin resistance.
BMC Endocr Disord (2026). https://doi.org/10.1186/s12902-025-02159-w

Image Credits: AI Generated

DOI: 10.1186/s12902-025-02159-w

Keywords: Metformin, childhood obesity, insulin resistance, zinc levels, adipose tissue, biomarkers.

This innovative framework emerges against a backdrop of expanding pharmacotherapy options targeting obesity, a multifactorial disease characterized by excessive adiposity and systemic metabolic disruptions. Recent years have witnessed an encouraging proliferation of novel agents, each possessing unique mechanisms of action. Yet, this diversity necessitates a structured approach to tailor treatments sparingly according to individual patient profiles, encompassing both weight reduction goals and obesity-associated pathologies.

Central to the EASO algorithm is a pioneering emphasis on the presence or absence of obesity-related complications as the pivotal determinant guiding medication selection. Dr. Ciudin, a co-first author, highlights that although multiple drugs are commercially available, semaglutide—a glucagon-like peptide-1 receptor agonist—and tirzepatide—a dual agonist targeting both gastric inhibitory polypeptide and GLP-1 receptors—demonstrate unrivaled efficacy profiles that justify their primacy across diverse clinical scenarios. This decisively shifts therapeutic paradigms from a one-size-fits-all model to a nuanced, evidence-driven practice.

The dual receptor agonist tirzepatide and the GLP-1 receptor agonist semaglutide have amassed robust evidence from randomized controlled trials and comprehensive meta-analyses, demonstrating profound, sustained total body weight reduction. The algorithm unequivocally endorses these agents when substantial weight loss is clinically warranted. Conversely, for moderate weight loss objectives, agents such as liraglutide, naltrexone–bupropion, and phentermine-topiramate retain therapeutic relevance, underscoring the importance of graduated treatment intensities.

The framework also introduces a dichotomous classification of obesity-related complications into “fat mass disease” and “sick fat disease,” distinguishing mechanically driven sequelae from immunometabolic dysfunctions. This mechanistic interpretation facilitates a tailored therapeutic lens. In fat mass disease, exemplified by obstructive sleep apnea (OSA) and knee osteoarthritis, tirzepatide and semaglutide are respectively recommended as first-line pharmacotherapies based on emerging but compelling trial data. Notably, semaglutide demonstrates superior efficacy in ameliorating osteoarthritis-related pain, a pivotal benefit beyond mere adiposity reduction.

In the realm of sick fat disease, which encapsulates metabolic and cardiovascular complications linked to adipose tissue inflammation and dysfunction, tirzepatide and semaglutide again dominate first-line recommendations. Their efficacy extends to crucial conditions such as prediabetes and type 2 diabetes, where these agents not only promote weight loss but also improve glycemic control, thereby addressing root pathophysiological mechanisms. Additionally, in cardiovascular disease contexts, semaglutide’s capacity to significantly reduce major adverse cardiovascular events (MACE) after prior incidents substantiates its preferential use.

Cardiometabolic complexities like heart failure, although under-explored pharmacologically, are also addressed within this framework. Preliminary data advocate for the consideration of either tirzepatide or semaglutide, pending further evidence. Furthermore, metabolic dysfunction-associated steatotic liver disease (MASH), a progressive condition contributing to hepatic fibrosis, responds favorably to tirzepatide, with semaglutide’s efficacy recently corroborated in phase 3 trials such as the ESSENCE study. These developments foreshadow imminent updates to the treatment algorithm incorporating semaglutide as a co-first line agent for MASH.

The authors conscientiously acknowledge profound economic and healthcare policy implications presented by these advanced incretin-based therapies. Though their costs can pose barriers within varied national frameworks, the argument is posited that early intervention to mitigate obesity and adipose tissue dysfunction is vital to circumvent the expensive sequelae of advanced complications and organ damage. Thus, holistic healthcare evaluations must integrate the long-term cost-effectiveness of early pharmacological treatment alongside immediate economic considerations.

Despite the compelling clinical data driving this new algorithm, the authors emphasize existing limitations, noting that many medications have yet to be extensively evaluated across the full spectrum of obesity-related complications. While weight loss is a validated surrogate endpoint for improvement in many conditions, direct evidence delineating specific therapeutic effects across complications such as chronic kidney disease, neurodegenerative illnesses, certain malignancies, polycystic ovary syndrome, and mental health remains emergent. This recognition underscores the dynamism and evolving nature of obesity pharmacotherapy research.

Professor Barbara McGowan underscores the complexity inherent in individualizing obesity treatment, advocating a comprehensive assessment framework that integrates adiposity severity, presence and extent of comorbidities, concurrent pharmacotherapies, as well as personal and socioeconomic factors. This patient-centric approach aims to harmonize clinical efficacy with patient values and expectations, fostering adherence and holistic outcomes in real-world settings.

Dr. Andreea Ciudin highlights the transformative impact of next-generation incretin therapies, describing the burgeoning class of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists as a revolution in obesity and complication management. She cautions that while this algorithm provides structured guidance, it is not a substitute for the nuanced clinical judgment necessary to navigate the heterogeneity of patient presentations and therapeutic responses.

Concluding with a forward-looking vision, EASO President Professor Volkan Yumuk commits to iterative revisions of this pharmacological framework, reflecting the rapid advances and accumulating evidence in the obesity treatment landscape. This commitment ensures that clinicians will have access to the most up-to-date, evidence-informed guidance for navigating the complexities of obesity pharmacotherapy.

As obesity continues to exert a staggering global health burden, this pioneering framework heralds a new era in which potent, mechanistically targeted therapies like semaglutide and tirzepatide ascend as foundational pillars of clinical care. Their integration promises not only profound weight loss but also meaningful mitigation of the multifaceted complications that render obesity a formidable clinical challenge.

Subject of Research: Pharmacological treatment strategies for obesity and obesity-related complications.

Article Title: Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO).

News Publication Date: 2 October 2025.

Web References: Not provided.

References: Clinical trials and meta-analyses detailed in the EASO publication, including the ESSENCE trial.

Image Credits: Not available.

Keywords: Semaglutide, Tirzepatide, Obesity pharmacotherapy, GLP-1 agonists, GIP/GLP-1 dual agonists, Obesity complications, Fat mass disease, Sick fat disease, Weight loss, EASO treatment algorithm, Metabolic dysfunction, Cardiovascular disease.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has garnered significant attention for its capacity to support weight loss while regulating glycemic control. Originally developed for individuals with type 2 diabetes, clinical evidence has shown its efficacy in promoting substantial weight reductions among non-diabetic populations. However, the transition from controlled clinical trials to practical, everyday settings reveals a different landscape—one that this study seeks to navigate by incorporating the WeGoTogether digital platform.

The WeGoTogether application represents a modern approach to patient engagement, marrying pharmacological interventions with behavioral support through technology. It offers users access to community support, educational resources, tracking tools, and other functionalities aimed at fostering adherence to weight loss regimens. This dual approach—medication coupled with digital support—aims to empower patients, making them active participants in their health journey. Understanding how these two elements interact can provide invaluable data on how to optimize treatment outcomes.

Participants in the study were observed to initiate treatment with Semaglutide 2.4 mg, reporting their experiences through the WeGoTogether platform over a specified period. The results yielded remarkable insights into both behavioral modifications and actual weight loss numbers, illuminating pathways for successful weight management strategies among various patient demographics. Even though Semaglutide has proven effective in clinical settings, translating those results to a real-world context illuminates the significance of ongoing support and encouragement.

Weight loss is often perceived as an uphill battle, deeply intertwined with individual psychology, environment, and access to resources. As such, the intervention of a digital application designed specifically for self-support stands out as an innovative solution. By enabling users to share their personal goals, challenges, and triumphs, WeGoTogether fosters a sense of community among participants. This study highlights how environmental factors combined with a robust medication like Semaglutide can create an ecosystem conducive to sustainable lifestyle changes.

An intriguing aspect of the research is the examination of adherence to both the medication and the WeGoTogether platform itself. Maintaining consistent use of Semaglutide is essential for the drug to manifest its weight-loss effects, while the continuous engagement with the application plays a vital role in motivating participants. Insights from the study suggest that users who remained active on the platform demonstrated greater weight loss and more significant behavioral changes compared to those who did not extensively utilize the application.

This suggests a symbiotic relationship between pharmacological treatment and digital health solutions, which could reshape how obesity is managed on a broader scale. Not merely dependent on the medication’s effectiveness, weight loss can significantly improve when supported by peer interactions and motivation. The implications of this are profound; it opens avenues for future research to explore the development and integration of similar platforms within traditional treatment frameworks.

Particularly noteworthy is the demographic diversity observed in the participants, consisting of various age groups, ethnic backgrounds, and pre-existing health conditions. Such a broad spectrum enhances the study’s validity, connecting findings to the larger population facing obesity—an issue that does not discriminate by age or ethnicity. By analyzing weight loss outcomes across these diverse backgrounds, the researchers are able to provide tailored recommendations that can be adapted to different patient profiles.

Another significant point addressed in the research is the psychological aspect of weight loss. The interaction between using the WeGoTogether app and the transformative journey of adopting Semaglutide invites exploration into self-efficacy and motivation. A key finding illustrates how users who are part of an encouraging community tend to have higher rates of self-motivation and are more likely to overcome barriers that typically discourage weight loss efforts.

Additionally, the longitudinal nature of the study offers compelling insights into how sustained use of both medication and digital support can lead to long-term weight management success. Traditional methods often emphasize initial weight loss, but this research indicates the vital importance of ongoing support and flexibility in treatment to foster lasting change.

The potential to expand the application of Semaglutide, in tandem with digital solutions like WeGoTogether, poses a fantastic opportunity for healthcare providers. Considering the increasing prevalence of obesity-related health issues, integrating innovative approaches into standard care protocols could result in significant improvements in patient health outcomes and quality of life.

In conclusion, the Toliver et al. study shines a light on a promising model combining modern pharmacotherapy with digital behavioral support in treating obesity. As more people turn to technology for assistance in managing their health, the insights from this research could spur a new wave of obesity treatment strategies that prioritize personalization and community involvement. The holistic approach illustrated in this study heralds a shift towards comprehensive care, where every aspect of a patient’s journey is valued and nurtured.

Continued research in this area is crucial to understanding the full breadth of the interaction between medication efficacy and digital support mechanisms. The results not only hold promise for addressing the growing obesity epidemic but also lay the groundwork for future innovations that could improve treatment paradigms across a range of chronic conditions.

Subject of Research: Real-world weight loss outcomes with Semaglutide 2.4 mg coupled with digital support.

Article Title: Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.

Article References:
Toliver, J.C., Divino, V., Ng, C.D. et al. Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.
Adv Ther (2025). https://doi.org/10.1007/s12325-025-03325-1

Image Credits: AI Generated

DOI: 10.1007/s12325-025-03325-1

Keywords: Semaglutide, weight loss, digital health, obesity management, real-world evidence.